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Abstract
Background: There is a well recognized risk of complications for both women and infants of a twin pregnancy,
increasing beyond 37 weeks gestation. Preterm birth prior to 37 weeks gestation is a recognized complication of a
twin pregnancy, however, up to 50% of twins will be born after this time.
The aims of this randomised trial are to assess whether elective birth at 37 weeks gestation compared with
standard care in women with a twin pregnancy affects the risk of perinatal death, and serious infant complications.
Methods/Design: Design: Multicentred randomised trial.
Inclusion Criteria: women with a twin pregnancy at 366 weeks or more without contraindication to continuation of
pregnancy.
Trial Entry & Randomisation: Following written informed consent, eligible women will be randomised from 36+6
weeks gestation. The randomisation schedule uses balanced variable blocks, with stratification for centre of birth
and planned mode of birth. Women will be randomised to either elective birth or standard care.
Treatment Schedules: Women allocated to the elective birth group will be planned for elective birth from 37
weeks gestation. Where the plan is for vaginal birth, this will involve induction of labour. Where the plan is for
caesarean birth, this will involve elective caesarean section. For women allocated to standard care, birth will be
planned for 38 weeks gestation or later. Where the plan is for vaginal birth, this will involve either awaiting the
spontaneous onset of labour, or induction of labour if required. Where the plan is for caesarean birth, this will
involve elective caesarean section (after 38 and as close to 39 weeks as possible).
Primary Study Outcome: A composite of perinatal mortality or serious neonatal morbidity.
Sample Size: 460 women with a twin pregnancy to show a reduction in the composite outcome from 16.3% to
6.7% with adjustment for the clustering of twin infants within mothers (p = 0.05, 80% power).
Discussion: This is a protocol for a randomised trial, the findings of which will contribute information about the
optimal time of birth for women with an uncomplicated multiple pregnancy at and beyond 37 weeks gestation.
Clinical Trial Registration: Current Controlled Trials ISRCTN15761056
Background
Twin pregnancies and perinatal mortality and morbidity
It is well established that the risks associated with a twin
pregnancy are greater for both mother and infants when
compared with singleton pregnancies. The increased
risk of stillbirth in twin pregnancies has been long
recognised, with a literature report from the Dublin
Lying-in Hospital dating to 1784, noting that “one-half
more twins die and near one-third more are stillborn,
than of single children”[1]. A number of more recent
studies have evaluated the association between advan-
cing gestational age and risk of morbidity and mortality
in multiple pregnancies [2-7].
We examined retrospective data from the South
Australian Pregnancy Outcome Unit, from 1991-2000,
and found that the stillbirth rate for twin pregnancies
was significantly higher than for singletons at each week
of gestational age (p < 0.0001) [4]. There was an increase
in stillbirth rate for singleton pregnancies, from 0.79 per
1000 births at 40 weeks gestation, to 3.1 per 1,000 births
at 42 weeks gestation. A similar trend was noted with
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twin pregnancies, but was seen at an earlier gestational
age, rising from 36 weeks [4]. Similarly, infants of twin
pregnancies had significantly higher neonatal mortality
rates than singleton infants at all gestational ages of birth
(p < 0.0001), with an increase evident from 35 weeks
gestation, and reaching a maximum at 40 weeks gestation
of 6.49 per 1,000 live births, almost 15 times greater than
that observed in singletons at the same gestational age [4].
Reported neonatal outcomes consistent with hypoxia
have included Apgar score of less than 7 at 5 minutes,
birth weight less than the third centile for gestational
age and sex [8], cord pH at birth of less than 7.00 [9],
admission to the neonatal intensive care unit (NICU),
need for ventilatory assistance, seizures within the first
24 hours of life, need for tube feeding and a diagnosis of
hypoxic ischaemic encephalopathy by ultrasound. These
adverse outcomes are those considered by experts as
important measures of term and post-term morbidity
[10]. When evaluating these measures as a composite
morbidity index, infants of twin pregnancies were found
to have a greater frequency of adverse outcomes at each
week of gestational age than infants of singleton preg-
nancies, being lowest at 37 weeks gestation (20.7 per
1,000) before increasing [4].
Luke and colleagues [6] retrospectively reviewed 163
twin pregnancies, and developed several models of the
“ideal twin pregnancy”. Using multivariate logistic
regression, the best model of intrauterine growth and
lowest perinatal morbidity was at an earlier gestation for
twins than for singletons. Using length of stay and
growth restriction criteria, 70 percent of “ideal” twin
pregnancies delivered between 35 and 38 weeks
gestation [6].
Cincotta and colleagues [3] retrospectively reviewed
data from Queensland (Australia), over a 10 year period
from 6,328 women with a twin pregnancy, to establish
the gestational age-specific stillbirth risk for both twins
and singleton gestations. On the basis of this informa-
tion, the authors concluded that the gestation-specific
rise in stillbirth rate seen in singletons at 40 weeks and
beyond occurs in twins from 36 weeks gestation and
onwards [3].
Minakami and Sato [7] have suggested that the esti-
mated date of confinement in twin pregnancies is between
37 and 38 weeks gestation. This is based on retrospective
information obtained from almost 89,000 infants born to
women with a twin pregnancy in Japan between 1989 and
1993. This study found a mean gestation at birth for twins
of 37 weeks, with the risk of stillbirth and early neonatal
death increasing after 38 weeks gestation. The lowest risk
of perinatal death in twin pregnancies at 38 weeks gesta-
tion corresponded to that observed in singleton pregnan-
cies at 43 weeks gestation [7].
Cheung and colleagues [2] obtained similar data from
the Swedish Medical Birth Registry for twin gestations
delivered between 1982 and 1995. The models used
identified a higher mortality rate among twins born
after 37 weeks when compared with singleton infants at
similar gestational age [2].
Hartley and colleagues [5] retrospectively analysed the
birth and death certificates, and hospital discharge data
for 8,150 twin pairs born in Washington State between
1987 and 1997. The lowest perinatal mortality rate for
twin gestations was found with birth at 37 weeks
gestation [5].
These studies indicate an increase in risk of stillbirth
in twin pregnancy with advancing gestational age, the
lowest risk of perinatal mortality and morbidity being
observed with birth between 36 and 38 weeks gestation
[2,3,5-7].
Benefits of induction of labour
Elective induction of labour has been proposed in a
number of clinical situations, with the aim of reducing
adverse outcomes for both women and their infants.
Induction of labour after 41 weeks gestation in women
with a singleton pregnancy has been shown to be asso-
ciated with a reduction in perinatal mortality [11].
Retrospective studies indicate that the risk of stillbirth
and early neonatal death in a twin gestation correlates
with that seen beyond 41 weeks in a singleton gestation
[2,3,5-7]. The question to then be considered relates to
prospectively defining the “post-term” twin pregnancy,
and to assess the role of induction of labour for women
with a post-term twin pregnancy in reducing perinatal
mortality. The potential advantages of elective timing of
birth in women with a twin pregnancy at 37 weeks’
gestation of a reduction in perinatal mortality and mor-
bidity have to be balanced against any associated
increase in the risk of caesarean section and potential
risks for the infants associated with early birth, including
respiratory distress syndrome and need for admission to
the neonatal unit.
Evidence for the optimal timing of birth for women with
a twin pregnancy at term: a systematic review of the
literature
In a Cochrane Systematic Review, we reviewed the lit-
erature to assess whether a policy of elective delivery
from 37 weeks’ gestation compared with an expectant
approach for women with an otherwise uncomplicated
twin pregnancy was associated with improved infant
outcome [12]. A single randomised controlled trial was
included addressing the role of induction of labour ver-
sus expectant management for women with a twin preg-
nancy from Japan [13].
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This trial, recruited 36 women with a twin pregnancy,
who gave birth after 37 weeks gestation, where the first
twin was in a cephalic presentation [13]. Nineteen
women were randomised to the expectant management
group that consisted of daily evaluation by non-stress
cardiotocograph (CTG), and twice weekly ultrasound
examination. The onset of spontaneous labour was
awaited provided no complications developed and fetal
well-being was confirmed. Seventeen women were ran-
domised to induction of labour, involving intravaginal
prostaglandin E2 followed by amniotomy and oxytocin
infusion when feasible. There were no losses to follow-
up. The authors did not describe the method of rando-
misation and allocation concealment.
There were no statistically significant differences iden-
tified in baseline characteristics between the two study
groups [13]. The average gestational age at birth in the
induction group was 37.5 +/- 0.4 weeks, significantly
earlier than in the expectant management group (39.0
+/- 1.1 weeks; p < 0.05). Seven women in the expectant
management group had prelabour rupture of the mem-
branes (PROM), and five neonates in this group had
meconium stained liquor. In comparison, no women in
the induction of labour group developed PROM (p <
0.05), and no infants were noted to have meconium
stained liquor (p < 0.05). There were no statistically sig-
nificant differences identified between the two treatment
groups with regards to mode of birth, infant birth
weight of less than 2500 grams, or Apgar score of less
than 7 at 5 minutes of age [13].
While the results of this trial [13] indicate no statisti-
cally significant differences between elective induction of
labour at 37 weeks’ gestation and continued expectant
management for the outcomes indicated, the small sam-
ple size means that it was underpowered to detect dif-
ferences in the clinical outcomes of interest, and further
information is required. On the basis of this single ran-
domised controlled trial, there are insufficient data avail-
able to support a practice of elective delivery from 37
weeks gestation for women with an otherwise uncompli-
cated twin pregnancy at term.
To summarise
Up to 50% of women with a twin pregnancy (approxi-
mately 1800 women in Australia per annum) will reach
37 weeks gestation and beyond. The risk of perinatal
mortality (stillbirth and neonatal death) and neonatal
morbidity associated with twin pregnancies has been
demonstrated to increase with advancing gestational
age. While elective birth at 37 weeks gestation may be a
safe and effective way to reduce the perinatal mortality
and morbidity in twins, the current evidence on the role
of elective birth at 37 weeks gestation for women with a
twin pregnancy is limited.
Aims of the trial
The aims of this randomised controlled trial are to
assess whether a policy of elective birth at 37 weeks
gestation compared with a policy of standard manage-
ment in women with a twin pregnancy affects the risk
of perinatal death (stillbirth or neonatal death); and the
risk of serious complications for the infant.
Trial hypotheses
The primary hypothesis of this randomised trial is that
for women with a twin pregnancy elective timing of
birth at 37 weeks gestation is associated with
• a reduction in serious adverse outcome for the
infant, defined as one or more of stillbirth, neonatal
death or significant infant morbidity.
The secondary hypotheses of the trial are that for
women and infants of a twin pregnancy elective timing
of birth at 37 weeks gestation compared with standard
management is associated with
• a reduction in antenatal medical and obstetric
complications
• a reduction in labour and birth complications
• a reduction in other infant complications
Methods and design
Study Design
Multicentred randomised controlled trial
Inclusion Criteria
All women with a twin pregnancy at gestational age of
366 weeks or more without a contraindication to conti-
nuation of pregnancy, presenting to the antenatal clinic
or ward of participating collaborating centres will be eli-
gible for trial participation.
Exclusion Criteria
Women with any of the following will be excluded
from the trial: intrauterine fetal death of one or both
fetuses at the time of trial entry; active labour; fetal
distress or non-reassuring fetal heart rate trace; mater-
nal or fetal compromise precluding continued antena-
tal surveillance.
Trial Entry
At the first antenatal clinic or upon diagnosis, all
women with a twin pregnancy will be given the trial
information sheet, counselled by a member of the
research team and encouraged to discuss the study with
her family. A member of the research team will then
obtain provisional, written, informed consent. To maxi-
mise the likelihood that women will receive the care
allocated at randomisation, eligible women will be
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randomised from 366 weeks gestation. Eligibility and
consent will be reconfirmed just prior to randomisation.
After the woman is eligible to be randomised, entry
details will be recorded on the trial entry form, and the
central telephone randomisation service at the Austra-
lian Research Centre for Health of Women and Babies,
Discipline of Obstetrics and Gynaecology, University of
Adelaide will be contacted. During a short telephone
call, information to check eligibility will be sought that,
describes the woman, enables stratification at randomi-
sation so that similar women are allocated to the treat-
ment arms, assists in follow-up and assists in the
analysis of results. If an eligible woman does not agree
to randomisation, minimal details will be recorded to
complete the requirements for reporting of clinical trials
(CONSORT).
Once all entry details are given at telephone randomi-
sation and eligibility confirmed, a study number will be
allocated to the woman by the central randomisation
office, and the group to which the woman is allocated
(either elective birth or standard care) will be stated. An
investigator not involved with the treatment allocation
of the women, using balanced variable blocks, will pre-
pare the randomisation schedule. Stratification will be
by collaborating centre and planned mode of birth
(planned caesarean section or planned vaginal birth).
Elective Birth Group
Women allocated to the elective birth group will be
planned for elective birth from 37 weeks gestation.
Where there is a plan for vaginal birth, this will involve
induction of labour. Where there is a plan for caesarean
birth, this will involve an elective caesarean section. The
planned mode of birth will be assessed and determined
by the woman and the obstetrician caring for her.
Standard Care Group
For women allocated to the standard care group, birth
will be planned for 38 weeks gestation or later, accord-
ing to the hospital where they expect to give birth.
Where there is a plan for vaginal birth, this will involve
either awaiting the spontaneous onset of labour, or
induction of labour if required. Where there is a plan
for caesarean birth, this will involve an elective caesar-
ean section (where possible booked after 38 weeks and
as close to 39 weeks gestation as possible). The planned
mode of birth will be assessed and determined by the
woman and the obstetrician caring for her.
If earlier birth (before 38 weeks gestation) is consid-
ered appropriate due to the development of complica-
tions, this will be carried out either by induction of
labour or by caesarean section, as determined by the
woman and the obstetrician caring for her. However,
the woman will remain in the standard care group for
the purposes of analysis.
Care of Women in Both Groups
Ongoing assessment of fetal well-being will be provided
according to the local hospital guidelines where the
woman is planned to give birth. The process of induc-
tion of labour will be carried out according to the usual
practices of the attending obstetrician and the hospital
involved. All women are recommended to have continu-
ous fetal heart rate monitoring by cardiotocograph
(CTG) when in active labour. The presence of a non-
reassuring fetal heart rate tracing will be managed by
performing fetal scalp pH sampling to assist decision
making where possible, or emergency caesarean section
as appropriate. The spectrum of analgesia and anaesthe-
sia should be available according to the woman’s choice.
In order to meet these requirements for care of
women participating in the trial, each collaborating cen-
tre should be able to perform continuous electronic
fetal heart rate monitoring during labour, be able to per-
form fetal scalp pH sampling in the setting of a non-
reassuring fetal heart rate trace, have on-site skilled
obstetric, anaesthetic and paediatric staff, be able to per-
form an emergency caesarean section, have an available
obstetric consultant for emergency back-up, and be able
to cross match blood. Care for the woman will be mana-
ged by the obstetric team with care of the infant by the
attending neonatologist.
Follow up of Women in Both Groups
After birth, information will be obtained relating to
birth and infant outcomes from the woman and infants’
case notes by the research assistant. The delivery form
will be completed after the woman has given birth.
Similarly, the postnatal and neonatal forms will be com-
pleted for each live born infant after discharge of both
mother and infants from hospital. After birth, placental
pathology will be performed to confirm the chorionicity
of the pregnancy.
Primary Study Endpoint
A composite mortality and morbidity index has been
chosen as the primary outcome for the trial. For a policy
of elective birth at 37 weeks gestation to be justified in
clinical practice, there must be an important benefit of
reduced perinatal mortality or serious adverse outcome
for the infants defined as one or more of the following:
• Perinatal mortality defined as any fetal death
after trial entry, or death of a liveborn infant within
28 days of age (excluding lethal congenital anoma-
lies); or
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• Serious neonatal morbidity defined as one or
more of the following, excluding lethal congenital
anomalies, and reflecting either asphyxia (birth
trauma (subdural or intracerebral haemorrhage,
spinal cord injury, basal skull fracture, other fracture,
peripheral nerve injury present at discharge from
hospital); birth weight ≤ 3rd centile for gestational
age at birth and infant sex [8]; Apgar score ≤ 4 at 5
minutes of age; cord pH ≤ 7.00 [9]; seizures at ≤ 24
hours age or requiring two or more drugs to control;
neonatal encephalopathy grade 3 or 4 [14]) or
immaturity (use of ventilation ≥ 24 hours; admission
to neonatal intensive care unit (NICU) ≥ 4 days;
severe respiratory distress syndrome (MAP ≥ 10 and
or FiO2 ≥ 0.8 with need for ventilation); neonatal
encephalopathy grade 3 or 4 [14]chronic lung disease
defined as continued oxygen requirement at 28 days
of life; proven necrotising enterocolitis; proven sys-
temic infection within 48 hours of birth treated with
antibiotics).
These definitions of adverse outcome are those used
by the Australian and New Zealand Neonatal Network,
[15] and those considered by experts as important mea-
sures of term and post-term neonatal morbidity [10].
Secondary Study Endpoints
1. Antenatal medical and obstetric complications
including: pre-eclampsia or eclampsia (systolic blood
pressure ≥ 140 mmHg and diastolic ≥ 90 mmHg on
two occasions four hours apart or more, and one of
proteinuria (≥ 300 mg/24 hours or spot urine creati-
nine ratio ≥ 30 mg/mmol), renal insufficiency (serum
plasma creatinine ≥ 0.09 mmol/L or oliguria), liver
disease (elevated serum transaminases &/or right
upper quadrant pain), neurological disturbances (con-
vulsions, hyperreflexia with clonus, severe headache
with hyperreflexia, persistent visual disturbances), or
haematological disturbances (thrombocytopaenia, dis-
seminated intravascular coagulopathy, haemolysis),)
[16] antepartum haemorrhage requiring hospitalisa-
tion; and abnormal umbilical artery Doppler study
(absent or reversed end diastolic flow as detected by
ultrasound examination).
2. Labour and birth complications including:
induction of labour for medical or obstetric compli-
cations; meconium stained liquor; cardiotocogram
(CTG) abnormality during labour (fetal tachycardia
(fetal heart rate greater than 160 bpm); fetal brady-
cardia (fetal heart rate less than 110 bpm); reduced
variability (less than 5 bpm); decelerations of the
fetal heart rate (early, late or variable)); instrumental
vaginal birth; emergency caesarean birth (all and for
fetal distress).
3. Adverse outcomes for the infantdefined as:
Apgar score <7 at 5 minutes; birthweight less than
10th centile for gestational age and infant sex; admis-
sion to neonatal intensive care unit (NICU) and
length of stay; incidence and severity of any neonatal
respiratory disease; use of and length of any mechan-
ical ventilation; use of and length of any tube
feeding.
4. Composite of serious neonatal outcomes
reflecting asphyxia defined as one or more of:
death due to asphyxial causes; birth trauma (sub-
dural or intra-cerebral haemorrhage, spinal cord
injury, basal skull fracture, other fracture, peripheral
nerve injury present at discharge from hospital);
birth weight ≤ 3rd centile for gestational age at birth
and infant sex [8]; Apgar score ≤ 4 at 5 minutes of
age; cord pH ≤ 7.00 [9]; seizures at ≤ 24 hours age
or requiring two or more drugs to control; neonatal
encephalopathy grade 3 or 4 [14]).
5. Composite of serious neonatal outcomes
reflecting immaturity defined as one or more of:
death due to immaturity causes; use of ventilation ≥
24 hours; admission to neonatal intensive care unit
(NICU) ≥ 4 days; severe respiratory distress syndrome
(MAP ≥ 10 and or FiO2 ≥ 0.8 with need for ventila-
tion); neonatal encephalopathy grade 3 or 4 [14];
chronic lung disease defined as continued oxygen
requirement at 28 days of life; proven necrotising
enterocolitis; proven systemic infection within 48
hours of birth treated with antibiotics.
Sample Size
The incidence of serious adverse infant outcome is the
principal endpoint of the trial. Using a composite neo-
natal morbidity and mortality index based on perinatal
mortality, admission to NICU for greater than or equal
to four days, and birthweight less than the third centile
for gestational age at birth and infant sex, the occur-
rence of serious adverse neonatal outcome for infants of
a twin pregnancy born at 37 weeks gestation or more is
estimated at 16.3% [4]. To reduce this to the rate of
6.7% seen in singleton infants at the same gestational
age [4], and adjusting for the clustering of twin infants
within mothers, a sample size of 460 women with a
twin pregnancy at ≥ 37 weeks gestation will be required,
using a p-value of 0.05 (two tailed) and power 80%.
Analysis and Reporting of Results
We will conduct an interim analysis when we have
recruited 50% of the total sample size (230 women).
The initial analysis will examine the baseline charac-
teristics of all randomised women, as an indication of
comparable treatment groups, and include maternal age,
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race, height, weight, smoking history, past obstetric his-
tory (including previous perinatal loss), and chorionicity
of the pregnancy. Any important differences in these
prognostic variables will be controlled for in subsequent
analyses. Outcome comparisons for women and infants
will be analysed for the primary and secondary out-
comes on an “intention to treat” basis, according to
treatment allocation at randomisation. Continuous out-
comes will be analysed using linear mixed model regres-
sion. Binary outcomes will be analysed using a
generalised linear mixed model with a log link function
and binomial distribution. A random effect to account
for clustering of babies from multiple births will be
included. If models do not converge, then alternative
methods of accounting for multiple births using robust
variance estimation will be explored. Results will be pre-
sented as relative risks with 95% confidence intervals.
The level of significance will be 0.05 and all p values
will be two-sided.
Pre-specified subgroup analyses will be by chorionicity
of the pregnancy (monochorionic or dichorionic); colla-
borating centre; and actual mode of birth.
Approval to conduct this study has been obtained
from the following research and ethics committees:
Women’s and Children’s Hospital (Adelaide, South Aus-
tralia); Lyell McEwin Health Service (Adelaide, South
Australia); The Royal Women’s Hospital (Melbourne,
Victoria); Sydney West Area Health Service (New South
Wales); Northern Sydney Central Coast (New South
Wales); Mater Health Services (Brisbane, Queensland);
Redcliffe-Caboolture Health Service (Queensland);
Logan Hospital (Queensland); Townsville Health Service
(Queensland); Mackay Base Hospital (Queensland); and
Auckland City Hospital (New Zealand).
Discussion
This is a protocol for a randomised trial assessing a pol-
icy of elective birth at 37 weeks gestation versus a policy
of continued expectant care for women with an uncom-
plicated twin pregnancy at term. The findings of this
trial will contribute to the currently available literature
regarding the optimal time of birth for women with an
uncomplicated multiple pregnancy at and beyond 37
weeks gestation.
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